GMEDGlobus Medical, Inc.
Is the price fair?
Undemanding: modest expectations priced in and cheap against its own history.
Priced for ~2% a year FCF growth. The price demands less than its three-year revenue growth of 42% a year, expectations look modest.
Cheap vs its own history: P/E 19.1 vs a 37.7 median over 41 quarters (−49% vs median).
Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What GMED's price assumes
Globus Medical, Inc. trades at 19.1× earnings against 26.2× for the median Medical Devices name, cheaper than its own group.
Trailing P/E · Medical Devices median 26.2 · cheaper than the typical name in its group
- Price / sales
- 3.91
Price / sales · today's price, fiscal year to Dec 31, 2025
- Free cash flow yield
- 6.6%
Free cash flow yield · Medical Devices median 4.5%
- Growth the price implies
- +2.0%
Growth the price implies · The price pays for +2.0% free cash flow growth a year for a decade; the business has delivered +84% a year over the last three.
Details›
- Price / booktoday's price, fiscal year to Dec 31, 2025
- 2.51
- EV / EBITtoday's price, fiscal year to Dec 31, 2025
- 22.8
- EV / salestoday's price, fiscal year to Dec 31, 2025
- 3.72
- Healthcare median P/E509 names
- 26.2
- Medical Devices median P/E64 names
- 26.2
- Free cash flow, trailing twelve months
- $756M
- Market capitalisation
- $11.5B
- 3-year revenue growth
- +42%
- 3-year free cash flow growth
- +84%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $109.61 |
| Its own P/E history, median | $146.86 |
| Its own P/E history, upper quartile | $196.91 |
| 52-week range | $55.10 – $96.82 |
| Today | $74.65 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.